Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICEBOAT
2024-516099-13-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing FMT capsule arm with Placebo capsule arm (2 arms). Planned start Oct 2024; status: authorised.
02
Drugs
allogeneic fecal microbiota
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2024-516099-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516099-13-00.